ResearcherGerman Cancer Research CenterActive in the last 2 years
Micah N. Sagini
Matched on ORCID iD 0000-0002-3934-2468; OpenAlex author ID A5068972973. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper
Papers 5
- EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. Co-author DOI 10.1016/j.peptides.2023.171111↗
- Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data from the Rat Model and Patients. Co-author DOI 10.1021/acsptsci.3c00013↗
- Lactosyl-sepharose binding proteins from pancreatic cancer cells show differential expression in primary and metastatic organs. Co-author DOI 10.1177/1535370220910691↗
- Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fphar.2020.549804↗
- The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment. Co-author DOI 10.18632/genesandcancer.173↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Martin Reinhold Berger · 5 shared papers, 2018–2024 · strength 0.84
- Paper Khasianine Affects the Expression of Sugar-Sensitive Proteins in Pancreatic Cancer Cells, Which Are Altered in Data fro… DOI 10.1021/acsptsci.3c00013↗
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111↗
- Paper Lactosyl-sepharose binding proteins from pancreatic cancer cells show differential expression in primary and metastatic… DOI 10.1177/1535370220910691↗
- Diana Behrens · 1 shared paper, 2024 · strength 0.20
- Wolf‐Georg Forssmann · 1 shared paper, 2024 · strength 0.20
- Doaa M. Ali · 1 shared paper, 2024 · strength 0.20
- Ergül Eyol · 1 shared paper, 2024 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.